Skip to main content
. 2023 Jun 6;12(12):3878. doi: 10.3390/jcm12123878

Figure 1.

Figure 1

Figure 1

Monthly sampling of visual and anatomical outcomes up to 6 months following initial intravitreal dexamethasone. (a) Mean visual acuity (Early Treatment Diabetic Retinopathy Study (ETDRS) letters; black and central subfoveal thickness (μm; red) following initial intravitreal dexamethasone. (b) Mean change in VA and central subfoveal thickness from baseline. Error bars signify 95% confidence intervals.